Astegolimab Market Insights

Key Factors Driving Astegolimab Growth

1) Massive COPD market opportunity with high unmet need

COPD remains one of the largest respiratory markets globally. According to the WHO, COPD is the third leading cause of death worldwide, causing ~3.5 million deaths annually. Millions of patients continue to experience frequent exacerbations despite triple inhaled therapy (ICS/LABA/LAMA), creating strong demand for biologics that reduce flare-ups.

Currently, Dupixent became the first biologic approved for COPD in 2024 for eosinophilic patients, but a large non-eosinophilic population still remains underserved. Astegolimab’s “all-comers” positioning (regardless of eosinophil count) was a major growth driver.

2) Differentiated IL-33/ST2 mechanism expands addressable population

Unlike IL-5 or IL-4 biologics that mainly target Type-2 inflammation, Astegolimab blocks the ST2 receptor, inhibiting IL-33 signaling—an upstream inflammatory pathway implicated in both eosinophilic and non-eosinophilic COPD.

This broader mechanism initially positioned Astegolimab as a potentially larger commercial opportunity than existing biologics because nearly 50–70% of COPD patients do not qualify for eosinophil-targeted biologics.

3) Positive Phase IIb ALIENTO data validated efficacy

A major commercial catalyst came in July 2025 when Roche announced that the Phase IIb ALIENTO study (n=1,301) met its primary endpoint.

Key results:

• 15.4% statistically significant reduction in annualized exacerbation rate (AER) at 52 weeks

• Tested in moderate-to-very severe COPD patients

• Included both former and current smokers

• Worked irrespective of blood eosinophil levels

This initially strengthened regulatory confidence and supported blockbuster expectations.

4) Favorable safety profile supports long-term biologic adoption

Roche reported that Astegolimab’s safety profile remained consistent with previous studies, with no new safety signals identified across both pivotal trials.

For chronic respiratory biologics, strong long-term tolerability is critical because patients may require years of treatment.

 

Astegolimab Recent Developments

In July 2025, Roche announced topline results from the pivotal Phase IIb ALIENTO (n=1,301) and the Phase III ARNASA (n=1,375) trials investigating Astegolimab compared to placebo, on top of standard of care maintenance therapy in people with moderate to very severe chronic obstructive pulmonary disease (COPD). The studies included a broad population: both former and current smokers, regardless of blood eosinophil count, who have a history of frequent exacerbations. 

“Astegolimab Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Astegolimab for potential indication like Asthma, Atopic dermatitis and Chronic obstructive pulmonary disease in the 7MM. A detailed picture of Astegolimab’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Astegolimab for potential indications. The Astegolimab market report provides insights about Astegolimab’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Astegolimab performance, future market assessments inclusive of the Astegolimab market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Astegolimab sales forecasts, along with factors driving its market.

 

Astegolimab Drug Summary

Astegolimab is an investigational human monoclonal antibody developed by Genentech (a member of Roche) that targets ST2, the receptor for Interleukin-33 signaling, a key driver of airway inflammation in respiratory diseases. By blocking IL-33/ST2 signaling, astegolimab is designed to reduce type 2 and non-type 2 inflammation, making it a potentially broader therapy for patients with severe Asthma and Chronic Obstructive Pulmonary Disease. The drug demonstrated promising reductions in asthma exacerbations in mid-stage trials, particularly in patients with low eosinophil counts who often have limited biologic treatment options. Astegolimab has been evaluated in Phase II and Phase III clinical studies, positioning it as a novel respiratory biologic that could expand treatment options beyond currently marketed eosinophil-targeted therapies. The report provides Astegolimab’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

 

Scope of the Astegolimab Market Report

The report provides insights into:

• A comprehensive product overview including the Astegolimab MoA, description, dosage and administration, research and development activities in potential indication like Asthma, Atopic dermatitis and Chronic obstructive pulmonary disease.

• Elaborated details on Astegolimab regulatory milestones and other development activities have been provided in Astegolimab market report.

• The report also highlights Astegolimab‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.

• The Astegolimab market report also covers the patents information, generic entry and impact on cost cut.

• The Astegolimab market report contains current and forecasted Astegolimab sales for potential indications till 2034.

• Comprehensive coverage of the late-stage emerging therapies for respective indications.

• The Astegolimab market report also features the SWOT analysis with analyst views for Astegolimab in potential indications.

 

Methodology

The Astegolimab market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

 

Astegolimab Analytical Perspective by DelveInsight

• In-depth Astegolimab Market Assessment

This Astegolimab sales market forecast report provides a detailed market assessment of Astegolimab for potential indication like Asthma, Atopic dermatitis and Chronic obstructive pulmonary disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Astegolimab sales data uptil 2034.

• Astegolimab Clinical Assessment

The Astegolimab market report provides the clinical trials information of Astegolimab for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Astegolimab Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Astegolimab Market Potential & Revenue Forecast

• Projected market size for the Astegolimab and its key indications

• Estimated Astegolimab sales potential (Astegolimab peak sales forecasts)

• Astegolimab Pricing strategies and reimbursement landscape

Astegolimab Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)

• Astegolimab Market positioning compared to existing treatments

• Astegolimab Strengths & weaknesses relative to competitors

Astegolimab Regulatory & Commercial Milestones

• Astegolimab Key regulatory approvals & expected launch timelines

• Commercial partnerships, licensing deals, and M&A activity

Astegolimab Clinical Differentiation

• Astegolimab Efficacy & safety advantages over existing drugs

• Astegolimab Unique selling points

 

Astegolimab Market Report Highlights

• In the coming years, the Astegolimab market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.

• The Astegolimab companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Astegolimab’s dominance.

• Other emerging products for Asthma, Atopic dermatitis and Chronic obstructive pulmonary disease are expected to give tough market competition to Astegolimab and launch of late-stage emerging therapies in the near future will significantly impact the market.

• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Astegolimab in potential indications.

• Analyse Astegolimab cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.

• Our in-depth analysis of the forecasted Astegolimab sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Astegolimab in potential indications.

 

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Astegolimab? How strong is Astegolimab’s clinical and commercial performance?

• What is Astegolimab’s clinical trial status in each individual indications such as Asthma, Atopic dermatitis and Chronic obstructive pulmonary disease and study completion date?

• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Astegolimab Manufacturers?

• What are the key designations that have been granted to Astegolimab for potential indications? How are they going to impact Astegolimab’s penetration in various geographies?

• What is the current and forecasted Astegolimab market scenario for potential indications? What are the key assumptions behind the forecast?

• What are the current and forecasted sales of Astegolimab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan? 

• What are the other emerging products available and how are these giving competition to Astegolimab for potential indications?

• Which are the late-stage emerging therapies under development for the treatment of potential indications?

• How cost-effective is Astegolimab? What is the duration of therapy and what are the geographical variations in cost per patient?